Phosphatidylinositol 3-Kinase Inhibition and Allogeneic Stem Cell Transplantation Can Overcome Chemotherapy Resistance in Refractory Burkitt Lymphoma.

IF 1.3 Q4 HEMATOLOGY

Journal of hematology Pub Date : 2025-03-01 Epub Date: 2025-03-18 DOI:10.14740/jh2043

Baldeep Wirk, Rajeswari Jayakumar, Jin Lim

{"title":"Phosphatidylinositol 3-Kinase Inhibition and Allogeneic Stem Cell Transplantation Can Overcome Chemotherapy Resistance in Refractory Burkitt Lymphoma.","authors":"Baldeep Wirk, Rajeswari Jayakumar, Jin Lim","doi":"10.14740/jh2043","DOIUrl":null,"url":null,"abstract":"<p><p>Induction multiagent chemotherapy can cure 70% of adult Burkitt lymphoma patients. However, for the remaining patients, the majority will relapse either during induction chemotherapy or within 6 months after initial complete remission, as in our patient. In this life-threatening presentation where no standard therapy exists with a response rate to salvage chemotherapy of 0% and a median survival of 6 weeks, there is an urgent need for novel, effective approaches to overcome chemoresistance in Burkitt lymphoma. Our report demonstrates that targeting B-cell receptor signaling via the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway with copanlisib can overcome chemotherapy resistance and achieve complete remission in relapsed Burkitt lymphoma. This novel approach, followed by consolidation with allogeneic hematopoietic stem cell transplantation can provide durable complete remission by harnessing the immune graft-versus-lymphoma effect in chemoresistant Burkitt lymphoma.</p>","PeriodicalId":15964,"journal":{"name":"Journal of hematology","volume":"14 2","pages":"94-99"},"PeriodicalIF":1.3000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045747/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/jh2043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Induction multiagent chemotherapy can cure 70% of adult Burkitt lymphoma patients. However, for the remaining patients, the majority will relapse either during induction chemotherapy or within 6 months after initial complete remission, as in our patient. In this life-threatening presentation where no standard therapy exists with a response rate to salvage chemotherapy of 0% and a median survival of 6 weeks, there is an urgent need for novel, effective approaches to overcome chemoresistance in Burkitt lymphoma. Our report demonstrates that targeting B-cell receptor signaling via the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway with copanlisib can overcome chemotherapy resistance and achieve complete remission in relapsed Burkitt lymphoma. This novel approach, followed by consolidation with allogeneic hematopoietic stem cell transplantation can provide durable complete remission by harnessing the immune graft-versus-lymphoma effect in chemoresistant Burkitt lymphoma.

查看原文本刊更多论文

磷脂酰肌醇3-激酶抑制和异体干细胞移植可以克服难治性伯基特淋巴瘤的化疗耐药。

诱导多药化疗可治愈70%的成人伯基特淋巴瘤患者。然而，对于剩余的患者，大多数会在诱导化疗期间或在最初完全缓解后6个月内复发，就像我们的患者一样。在这种危及生命的表现中，目前还没有标准的治疗方法，补救性化疗的反应率为0%，中位生存期为6周，迫切需要新的、有效的方法来克服伯基特淋巴瘤的化疗耐药。我们的报告表明，通过磷脂酰肌醇3-激酶/蛋白激酶B （PI3K/AKT）途径靶向B细胞受体信号通路的copanlisib可以克服化疗耐药并实现复发性Burkitt淋巴瘤的完全缓解。这种新颖的方法，随后与同种异体造血干细胞移植巩固，可以提供持久的完全缓解，利用免疫移植物抗淋巴瘤效应在化疗耐药的伯基特淋巴瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of hematology HEMATOLOGY-

自引率

0.00%

发文量